WO2001032926A3 - Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes - Google Patents

Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes Download PDF

Info

Publication number
WO2001032926A3
WO2001032926A3 PCT/US2000/030051 US0030051W WO0132926A3 WO 2001032926 A3 WO2001032926 A3 WO 2001032926A3 US 0030051 W US0030051 W US 0030051W WO 0132926 A3 WO0132926 A3 WO 0132926A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiogenesis
methods
differentially expressed
polypeptides encoded
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/030051
Other languages
English (en)
Other versions
WO2001032926A2 (fr
Inventor
Fuad Mehraban
Mary Gerritsen
Luca Rastelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
CuraGen Corp
Original Assignee
Genentech Inc
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, CuraGen Corp filed Critical Genentech Inc
Priority to JP2001535606A priority Critical patent/JP2003525595A/ja
Priority to CA002389751A priority patent/CA2389751A1/fr
Priority to AU14493/01A priority patent/AU784338B2/en
Priority to EP00976760A priority patent/EP1287161A2/fr
Publication of WO2001032926A2 publication Critical patent/WO2001032926A2/fr
Anticipated expiration legal-status Critical
Publication of WO2001032926A3 publication Critical patent/WO2001032926A3/fr
Priority to AU2006202570A priority patent/AU2006202570A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

L'invention concerne des séquences d'acide nucléique et leurs polypeptides codés, exprimés de manière différentielle dans l'angiogénèse. L'invention concerne également des techniques de stimulation ou d'inhibition de l'angiogénèse chez les mammifères, notamment les humains. Elle concerne en outre des compositions pharmaceutiques à base de polypeptides, d'agonistes, ou d'antagonistes. Elle concerne, enfin, des techniques permettant de diagnostiquer et de traiter des troubles de l'angiogénèse notamment la cicatrisation de blessures et le cancer.
PCT/US2000/030051 1999-11-01 2000-11-01 Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes Ceased WO2001032926A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001535606A JP2003525595A (ja) 1999-11-01 2000-11-01 脈管形成に含まれる差動発現遺伝子、それにコードされるポリペプチド、及びそれを用いた方法
CA002389751A CA2389751A1 (fr) 1999-11-01 2000-11-01 Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes
AU14493/01A AU784338B2 (en) 1999-11-01 2000-11-01 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
EP00976760A EP1287161A2 (fr) 1999-11-01 2000-11-01 Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes
AU2006202570A AU2006202570A1 (en) 1999-11-01 2006-06-16 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16269999P 1999-11-01 1999-11-01
US60/162,699 1999-11-01
US19680200P 2000-04-13 2000-04-13
US60/196,802 2000-04-13
US70335000A 2000-10-31 2000-10-31
US09/703,350 2000-10-31

Publications (2)

Publication Number Publication Date
WO2001032926A2 WO2001032926A2 (fr) 2001-05-10
WO2001032926A3 true WO2001032926A3 (fr) 2002-12-05

Family

ID=27388787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030051 Ceased WO2001032926A2 (fr) 1999-11-01 2000-11-01 Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes

Country Status (4)

Country Link
JP (1) JP2003525595A (fr)
AU (2) AU784338B2 (fr)
CA (1) CA2389751A1 (fr)
WO (1) WO2001032926A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US8969344B2 (en) 2005-08-02 2015-03-03 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US9006256B2 (en) 2006-05-18 2015-04-14 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
US9504746B2 (en) 2004-09-17 2016-11-29 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2798674B1 (fr) * 1999-09-21 2004-01-30 Mahmood Salman Al Procede d'identification de nouveaux genes impliques dans la regulation de l'angiogenese, etude de ces genes et leur utilisation a des fins therapeutiques
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
JP4486815B2 (ja) * 2001-09-27 2010-06-23 バイオノミックス リミテッド ヒト血管形成遺伝子に対するｄｎａ配列
AU2003286746A1 (en) * 2002-10-29 2004-05-25 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
US7407660B2 (en) 2003-04-16 2008-08-05 Genentech, Inc. Methods and compositions for selective modulation of vascularization
WO2005015227A1 (fr) * 2003-08-08 2005-02-17 Roche Diagnostics Gmbh Proteine t-plastine (plst) utilisee comme marqueur du cancer colorectal
WO2005015226A1 (fr) * 2003-08-08 2005-02-17 Roche Diagnostics Gmbh Utilisation de la plastine t de proteine (plst) comme marqueur du cancer colono-rectal
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
EP1721158A4 (fr) * 2004-01-13 2008-07-30 Rigel Pharmaceuticals Inc Modulateurs d'angiogenese
JP2006333770A (ja) * 2005-06-01 2006-12-14 Japan Science & Technology Agency 血管炎（ａｎｇｉｉｔｉｓ）患者の血液細胞特異的遺伝子群
WO2007022625A1 (fr) * 2005-08-22 2007-03-01 Caprion Pharmaceuticals Inc. Procedes de reversion d'expression peptidique, et utilisations
CN101316590B (zh) 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
JP2009537123A (ja) * 2006-05-18 2009-10-29 サノフィ−アベンティス Ａｄａｍｔｓ４遺伝子およびンパク質の多型の使用
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
EP2994158A2 (fr) 2013-05-10 2016-03-16 Aarhus Universitet Régulateur de pappalysine
EP2997377B1 (fr) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de l' endometre vis-à-vis de composés lenvatinib
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
EP3624800A4 (fr) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. Traitement du carcinome hépatocellulaire
WO2024037387A1 (fr) * 2022-08-19 2024-02-22 Tianjin Yunjian Medical Technology Co., Ltd. Biomarqueurs sanguins et procédés de diagnostic de la maladie de kawasaki aiguë

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023075A1 (fr) * 1992-05-14 1993-11-25 Oncologix, Inc. Traitement du syndrome de permeabilite capillaire diffuse et des maladies induites par la collagenase par administration d'inhibiteurs de la metalloproteinase matricielle
WO1997030065A1 (fr) * 1996-02-16 1997-08-21 Millennium Pharmaceuticals, Inc. Compositions et procedes de traitement et de diagnostic des maladies cardio-vasculaires
WO1998031709A1 (fr) * 1997-01-17 1998-07-23 Hoechst Aktiengesellschaft Anticorps qui se lient aux domaines de liaison de nidogene de la laminine, leur production et leur utilisation
WO2000052051A1 (fr) * 1999-03-01 2000-09-08 Aventis Pharma Deutschland Gmbh Derives peptidiques a faible masse moleculaire comme inhibiteurs de l'interaction laminine/nidogene
WO2000055174A1 (fr) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Sequences de genes et polypeptides associees au cancer de la prostate de l'homme
WO2001073025A2 (fr) * 2000-03-29 2001-10-04 Beth Israel Deaconess Medical Center, Inc. Proprietes anti-angiogenes et anti-tumorales de la vascostatine et d'autres domaines nidogenes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2387685A1 (fr) 1999-10-27 2001-05-03 Human Genome Sciences, Inc. Proteines et acides nucleiques de stanniocalcine et methodes afferentes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023075A1 (fr) * 1992-05-14 1993-11-25 Oncologix, Inc. Traitement du syndrome de permeabilite capillaire diffuse et des maladies induites par la collagenase par administration d'inhibiteurs de la metalloproteinase matricielle
WO1997030065A1 (fr) * 1996-02-16 1997-08-21 Millennium Pharmaceuticals, Inc. Compositions et procedes de traitement et de diagnostic des maladies cardio-vasculaires
WO1998031709A1 (fr) * 1997-01-17 1998-07-23 Hoechst Aktiengesellschaft Anticorps qui se lient aux domaines de liaison de nidogene de la laminine, leur production et leur utilisation
WO2000052051A1 (fr) * 1999-03-01 2000-09-08 Aventis Pharma Deutschland Gmbh Derives peptidiques a faible masse moleculaire comme inhibiteurs de l'interaction laminine/nidogene
WO2000055174A1 (fr) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Sequences de genes et polypeptides associees au cancer de la prostate de l'homme
WO2001073025A2 (fr) * 2000-03-29 2001-10-04 Beth Israel Deaconess Medical Center, Inc. Proprietes anti-angiogenes et anti-tumorales de la vascostatine et d'autres domaines nidogenes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIRD IAN N ET AL: "Homophilic PECAM-1(CD31) interactions prevent endothelial cell apoptosis but do not support cell spreading or migration.", JOURNAL OF CELL SCIENCE, vol. 112, no. 12, June 1999 (1999-06-01), pages 1989 - 1997, XP002193379, ISSN: 0021-9533 *
KOHFELDT E ET AL: "NIDOGEN-2:A NEW BASEMENT MEMBRANE PROTEIN WITH DIVERSE BINDING PROPERTIES", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 282, 1998, pages 99 - 109, XP002928990, ISSN: 0022-2836 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504746B2 (en) 2004-09-17 2016-11-29 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
US8969344B2 (en) 2005-08-02 2015-03-03 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US9006256B2 (en) 2006-05-18 2015-04-14 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same

Also Published As

Publication number Publication date
AU2006202570A1 (en) 2006-07-06
AU784338B2 (en) 2006-03-16
AU1449301A (en) 2001-05-14
WO2001032926A2 (fr) 2001-05-10
CA2389751A1 (fr) 2001-05-10
JP2003525595A (ja) 2003-09-02

Similar Documents

Publication Publication Date Title
WO2001032926A3 (fr) Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes
IL147442A0 (en) Promotion or inhibition of angiogenesis and cardiovscularization by tumor necrosis factor ligand/receptor homologs
WO2002000690A3 (fr) Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
WO2001072962A3 (fr) Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique
WO2003030934A3 (fr) Formulations cpg et procedes y relatifs
EP1140840A4 (fr) Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
EP2022800A3 (fr) Compositions utilisés dans la thérapie et le diagnostic du cancer des ovaires
WO2001045730A3 (fr) Recepteur tweak
WO2003024392A3 (fr) Compositions et procedes pour le diagnostic et le traitement des tumeurs
WO2002062763A3 (fr) Inhibition de raf kinase a l'aide de quinolyl, isoquinolyl ou pyridyl urees
WO2001023405A3 (fr) Traitement therapeutique d'affections causees par le recepteur androgene
IL146482A0 (en) Tek antagonists
WO1999029729A3 (fr) Fonction et utilisation de l'antagoniste du recepteur de la neuropiline
WO2001001748A3 (fr) Composés se liant à her2
CA2359510A1 (fr) Diphenylurees a substituants .omega.-carboxyaryles, inhibitrices de kinase raf
WO2002085857A3 (fr) Inhibition de la kinase raf a l'aide d'urees de quinolyl, d'isoquinolyl ou de pyridyl
EP1445317A3 (fr) Compositions et procédés de diagnostic et traitement de tumeurs
WO2001036640A3 (fr) Gene humain fgf-21 et produits d'expression genique
WO1999054461A3 (fr) Sequences d'acide nucleique humaines provenant d'une tumeur de l'endometre
WO2001070977A3 (fr) Molecules analogues au recepteur du facteur de croissance du fibroblaste, et leurs utilisations
WO1998014596A3 (fr) Tyrosine phosphatases proteiques associees a des maladies
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2001018046A3 (fr) Sequences de tumeurs ovariennes et procedes d'utilisation correspondants
ATE242242T1 (de) Derivate von imidazo(1,2-a)pyridin zur behandlung von gastrointestinalen krankheiten
WO2001042474A3 (fr) Molecules de type interferon et utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WD Withdrawal of designations after international publication

Free format text: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 535606

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2389751

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14493/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000976760

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000976760

Country of ref document: EP